Quinupristin is an antibiotic agent used in the treatment of serious vancomycin-resistant Enterococcus faecium bacteremia as well as complicated skin and skin structure infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
- Mechanism
- Curator reviewed
Quinupristin inhibits the late phase of protein synthesis in the bacterial ribosome. Dalfopristin binds to the 23S portion of the 50S ribosomal subunit, and changes the conformation it, enhancing the binding of quinupristin by a factor of about 100. In addition, it inhibits peptidyl transferase. Quinupristin binds to a nearby site on the 50S ribosomal subunit and prevents elongation of the polypeptide as well as causing incomplete chains to be released.
- Primary indication
- For the treatment of bacterial infections (usually in combination with dalfopristin).Curator reviewed · 3 structured indications
- Formula / weight
- C53H67N9O10S · 1022.23 g/mol (avg)
- First approval
- Canada, 2005 · United States, 1999
- Code names
- RP 57669
- Brand names
Resolves to
WTHRRGMBUAHGNI-LCYNINFDSA-NSMILES[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1What you can answer from here — as of August 31, 2026
Which drugs share a target with Quinupristin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account